← Al het nieuws

Synerkine Pharma Raises €3.3 M in Series A Financing


Synerkine Pharma has successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the company’s founders. Synerkine Pharma focuses on developing novel fusion proteins for the treatment of chronic pain. The company is a spin off from University Medical Center Utrecht and was founded in 2018

Hans Preusting, co-founder and CEO of Synerkine Pharma, said: “We are delighted with the closing of the Series A financing. The proceeds will allow us to deliver a preclinical proof of concept in steoarthritis and neuropathic pain over the next two years. Our lead compound licensed from the University Medical Center Utrecht (UMCU), a fusion protein of IL4 and IL10, has been shown to significantly reduce chronic pain in multiple pre-clinical models. The therapeutic potential of fusion proteins that mimic endogenous immune molecules and are devoid of the typical analgesic side-effects is substantial in a broad range of pain indications.”